Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative ...

A study in the Journal of Clinical Oncology provides additional support for enhanced activity and safety for a regimen of TKI therapy (osimertinib) when administered with anti-angiogenic therapy ...

GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...

Investigator studied current treatment patterns and attrition rates in metastatic clear cell renal cell carcinoma using a large, US nationwide cohort.

Meanwhile, J&J is also exploring the use of amivantamab in patients who have failed TKI therapy and only have chemo as an option. Both lazertinib and amivantamab – which was developed using ...

following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy. This is the first TROP2 ADC drug approved for marketing in lung cancer globally. Compared ...

For third-line treatment, TKI was the most common therapy in both cohorts 1 (47.2%) and 2 (50.9%). Other common third-line treatments in cohort 1 included PD-1 inhibitor monotherapy (23.3% ...